ENB Therapeutics, Inc. was founded with the mission to overcome immunotherapy resistance in cancer treatment. The company's vision is to revolutionize cancer therapy by developing small molecule inhibitors targeting novel pathways within the tumor microenvironment. Their primary product, ENB-003, is designed to enhance the efficacy of existing immunotherapies, particularly for melanoma and other resistant cancers. ENB Therapeutics focuses on serving patients in the United States, aiming to provide innovative solutions for those who do not respond to current cancer treatments.

Notable affiliations include a clinical collaboration with Coherus BioSciences and the Cancer Research Institute, highlighting the potential of ENB-003 in combination therapies. Key achievements include advancing their lead candidate through significant stages of clinical trials and receiving recognition within the biopharmaceutical industry for their novel approach. ENB Therapeutics' impact lies in their potential to significantly improve outcomes for cancer patients who have limited options, thereby addressing a critical unmet need in oncology.